drug · protein
Ozempic
pre_registrationupdated 3mo agoby Novo Nordisk AS🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugWegovy222 co-mentions · 76 sources
- tagApproval176 co-mentions · 44 sources
- drugWegovy Pill168 co-mentions · 74 sources
- drugRybelsus121 co-mentions · 73 sources
- drugsemaglutide120 co-mentions · 72 sources
- tagSmall Molecule35 co-mentions · 18 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc23 co-mentions · 4 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
targets
Glucagon-like peptide 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying Ozempic
- phase3A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- phase3A Study of BGM0504 in Early T2DM With Obesity
- phase2Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase4Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
- phase1Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
News(10)
- Scholar Rock rejigs approval filing after FDA flags violations at Novo plantDespite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.biospace · 14h ago
- Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsMedicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.stat · 19h ago
- Novo Nordisk’s CFO on the oral Wegovy rollout and beyondNovo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.fiercebiotech · 4d ago
- Actimed gets back rights to wasting disease drug, ending $126M deal with FaradayActimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.fiercebiotech · 5d ago
- Lilly confident in slow and steady Foundayo launch, as ex-US sales shineFoundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.biospace · 6d ago
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 6d ago
- Lilly climbs, Novo falls as obesity drug battle intensifiesA research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.biopharma_dive · 6d ago
- Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the e…biospace · 6d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 6d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 6d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that